AbbVie-Allergan Deal Foes Try Again to Spur an FTC Crackdown

AbbVie and Allergan’s megamerger is likely in the final stages of review after the pair agreed to offload three drugs, including IL-23 hopeful brazikumab. But a cadre of union and consumer groups say that’s not enough—and they’re taking another stab at turning regulators against the combo, according to a FiercePharma report.

Despite AbbVie’s assurances that divesting brazikumab would help level the competitive playing field after its $63 billion megamerger with Allergan, the proposed sale would not accomplish that goal, the groups told the Federal Trade Commission (FTC) in a letter (PDF) Tuesday. 

Read the full article.